PPL and idiopathic interstitial pneumonia: The presence of lung B-cell infiltration, activated TLS, and autoantibodies to PPL and other autoantigens (12) suggests that the use of anti-CD20 monoclonal antibodies like rituximab or ocrelizumab (38, 39), now being used in non-IPF ILDs, could be effective in the treatment of IPF.